What does “GLP-1” really mean?

GLP-1 is the acronym for glucagon-like peptide type 1, a signal that the body produces naturally after eating. In simple terms, it is part of the communication between the intestine, the pancreas and the brain. Medications in this family mimic or prolong part of that signal.

On the Internet, “GLP-1” is used as a general label for various treatments, but it is advisable not to confuse family, active ingredient and brand. Semaglutide is an active ingredient related to GLP-1. Tirzepatide acts on two receptors, GIP and GLP-1. Wegovy and Mounjaro are specific brands with their own instructions and Summaries of Product Characteristics (SmPCs).

How can they help control weight?

Weight control does not depend only on willpower. Appetite, satiety, response to food, sleep, other medications, illness, and environment all play a role. Treatments related to GLP-1 modify some of the signals that intervene in that system.

European regulatory information describes effects on the regulation of appetite and intake. In practice, some people notice satiety sooner or less interest in large amounts of food. This can facilitate an energy deficit, but the medication alone does not decide the quality of the diet nor automatically preserve muscle mass.

It is not an isolated treatment

Official indications for weight control place these medications as a complement to a diet with fewer calories and greater physical activity. That is why a good plan is not limited to prescribing: it includes realistic goals, sufficient nutrition, adapted movement, monitoring of adverse effects and review of results.

Who can it be valued for?

According to European information, Wegovy and Mounjaro are used for weight control in adults with obesity, or in overweight adults when there is at least one weight-related health problem. The exact criteria are expressed by body mass index (BMI), but BMI is not the only part of the assessment.

The doctor also needs to know relevant history, digestive symptoms, pregnancy or pregnancy planning, usual medications, previous treatments, metabolic health, expectations, and any situation that may modify safety. A consultation does not guarantee a prescription: it allows you to determine if there is a reasonable indication and if additional information is needed.

Semaglutide and tirzepatide: similar, but not interchangeable

Comparing just the mean percentage of weight loss from two studies can be misleading. Trial populations, duration, doses, monitoring, and criteria may be different. Furthermore, an average does not predict what will happen for a specific person.

The useful question is not only “which one loses the most?”, but “which one is indicated, what risks should I review, what can I maintain in the long term, and how will we know if it is helping me?”

What to expect during treatment

The experience is usually not linear. Appetite may change before weight. Some weeks show more variation than others, and daily weight can fluctuate due to hydration, salt, intestinal transit, or menstrual cycle. That is why monitoring must look at the trend and not at an isolated figure.

A reasonable expectation includes:

• a progressive start and reviews before dose changes;
• possible digestive discomfort, especially during adaptation;
• check if the diet is still sufficient and balanced;
• maintain physical activity, with attention to strength and function;
• decide with the doctor if the benefit outweighs the adverse effects;
• plan maintenance, not just the loss phase.

Copying someone else’s regimen, speeding up increases, or purchasing the medication outside the legal circuit can increase risk and eliminates essential controls on authenticity, storage, and monitoring.

Safety: common effects and signs that should not be ignored

Gastrointestinal discomfort – such as nausea, diarrhea, vomiting or constipation – are among the effects described with these treatments. Its intensity and duration vary. If they cause difficulty drinking, signs of dehydration or significant worsening, you should consult.

The Summaries of Product Characteristics (SmPCs) include warnings and situations that require individual assessment. These include a history or symptoms compatible with pancreatitis, certain gastrointestinal problems, concomitant use with some diabetes medications, and considerations related to pregnancy. The complete list depends on the product and should be reviewed in its official information.

What a responsible clinical process should be like

Helpful follow-up asks about both benefits and problems. If the person can barely eat, loses weight too quickly, has persistent effects, or has no benefit, the plan should be revised. Continuing “because it is fashionable” is not a clinical criterion.

Questions to bring to the consultation

• Do I meet the indication criteria for weight control?
• Is there any history or medication that changes my risk?
• Do I need analysis or other evaluation before starting?
• What effects are expected and which require help?
• How will we measure benefit and when will we review the plan?
• What strategy will we use to conserve muscle mass and maintain results?